 The number of Series A warrants and Series B warrants purchased by the underwriters in the over-allotment option has been corrected to 128,328. Loma Linda, CA, July 06, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. Aditxt the Company ADTX, a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today announced the closing of its previously announced 11.0 million initial public offering of 1,226,668 units, each unit consisting of one share of common stock, one Series A warrant, and one Series B warrant. In addition, the underwriters partially exercised their overallotment option and purchased Series A warrants to purchase an aggregate of 128,328 shares of common stock and Series B warrants to purchase an aggregate of 128,328 shares of common stock. 